Prudential Financial Inc. boosted its stake in Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) by 111.4% during the second quarter, Holdings Channel reports. The institutional investor owned 197,656 shares of the specialty pharmaceutical company’s stock after buying an additional 104,140 shares during the period. Prudential Financial Inc. owned about 0.40% of Supernus Pharmaceuticals worth $4,026,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of SUPN. Teacher Retirement System of Texas boosted its stake in Supernus Pharmaceuticals by 29.6% in the second quarter. Teacher Retirement System of Texas now owns 5,468 shares of the specialty pharmaceutical company’s stock valued at $111,000 after buying an additional 1,249 shares during the period. Acrospire Investment Management LLC boosted its stake in Supernus Pharmaceuticals by 33.1% in the second quarter. Acrospire Investment Management LLC now owns 8,252 shares of the specialty pharmaceutical company’s stock valued at $168,000 after buying an additional 2,052 shares during the period. Bank of Montreal Can bought a new stake in Supernus Pharmaceuticals during the second quarter valued at approximately $199,000. Boothbay Fund Management LLC bought a new stake in Supernus Pharmaceuticals during the first quarter valued at approximately $203,000. Finally, BNP Paribas Arbitrage SA boosted its stake in Supernus Pharmaceuticals by 126.3% in the second quarter. BNP Paribas Arbitrage SA now owns 11,478 shares of the specialty pharmaceutical company’s stock valued at $234,000 after buying an additional 6,407 shares during the period. 94.62% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) opened at 20.69 on Tuesday. Supernus Pharmaceuticals Inc. has a 12-month low of $9.51 and a 12-month high of $26.84. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of 42.22 and a beta of 1.73. The firm has a 50-day moving average of $23.53 and a 200 day moving average of $20.40.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.05. The firm had revenue of $50.40 million for the quarter, compared to the consensus estimate of $49.67 million. Supernus Pharmaceuticals had a net margin of 14.94% and a return on equity of 20.99%. The company’s revenue for the quarter was up 43.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.03 EPS. On average, equities research analysts expect that Supernus Pharmaceuticals Inc. will post $0.68 earnings per share for the current year.
Several analysts have recently commented on the stock. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Jefferies Group set a $28.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, October 13th. Northland Securities cut shares of Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price target on the stock. in a research note on Monday, July 18th. Finally, Piper Jaffray Cos. lowered shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 price objective on the stock. in a report on Monday, July 18th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $25.25.
In other news, CFO Gregory S. Patrick sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $25.00, for a total value of $50,000.00. Following the transaction, the chief financial officer now owns 3,616 shares in the company, valued at approximately $90,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.10% of the stock is currently owned by insiders.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc. (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.